CliffBio
biologic

Enjaymo

sutimlimab-jome

Loss of exclusivityFebruary 2034projected — 12-year biologic exclusivity estimate
CompanyRecordati Rare Diseases Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameEnjaymo
Active ingredientsutimlimab-jome
Strength1,100MG/22ML (50MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2022
Marketing statusRx

More from Recordati Rare Diseases Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.